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Alzheimer’s disease has a preclinical stage when cerebral amyloid-b deposition occurs before symptoms emerge, and when amyl-
oid-b-targeted therapies may have maximum benefits. Existing amyloid-b status measurement techniques, including amyloid PET
and CSF testing, are difficult to deploy at scale, so blood biomarkers are increasingly considered for screening. We compared three
different blood-based techniques—liquid chromatography-mass spectrometry measures of plasma amyloid-b, and single molecule
array (Simoa) measures of plasma amyloid-b and phospho-tau181—to detect cortical 18F-florbetapir amyloid PET positivity
(defined as a standardized uptake value ratio of 40.61 between a predefined cortical region of interest and eroded subcortical
white matter) in dementia-free members of Insight 46, a substudy of the population-based British 1946 birth cohort. We used logis-
tic regression models with blood biomarkers as predictors of amyloid PET status, with or without age, sex and APOE e4 carrier
status as covariates. We generated receiver operating characteristics curves and quantified areas under the curves to compare the
concordance of the different blood tests with amyloid PET. We determined blood test cut-off points using Youden’s index, then
estimated numbers needed to screen to obtain 100 amyloid PET-positive individuals. Of the 502 individuals assessed, 441
dementia-free individuals with complete data were included; 82 (18.6%) were amyloid PET-positive. The area under the curve for
amyloid PET status using a base model comprising age, sex and APOE e4 carrier status was 0.695 (95% confidence interval:
0.628–0.762). The two best-performing Simoa plasma biomarkers were amyloid-b42/40 (0.620; 0.548–0.691) and phospho-tau181
(0.707; 0.646–0.768), but neither outperformed the base model. Mass spectrometry plasma measures performed significantly better
than any other measure (amyloid-b1-42/1-40: 0.817; 0.770–0.864 and amyloid-b composite: 0.820; 0.775–0.866). At a cut-off point
of 0.095, mass spectrometry measures of amyloid-b1-42/1-40 detected amyloid PET positivity with 86.6% sensitivity and 71.9% spe-
cificity. Without screening, to obtain 100 PET-positive individuals from a population with similar amyloid PET positivity preva-
lence to Insight 46, 543 PET scans would need to be performed. Screening using age, sex and APOE e4 status would require 940
individuals, of whom 266 would proceed to scan. Using mass spectrometry amyloid-b1-42/1-40 alone would reduce these numbers
to 623 individuals and 243 individuals, respectively. Across a theoretical range of amyloid PET positivity prevalence of 10–50%,
mass spectrometry measures of amyloid-b1-42/1-40 would consistently reduce the numbers proceeding to scans, with greater cost
savings demonstrated at lower prevalence.
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Introduction
A core early feature of Alzheimer’s disease is brain depos-
ition of amyloid-b, which is detectable in vivo using amyloid
PET ligands binding fibrillar amyloid-b (Klunk et al., 2004;
Morris et al., 2016), and by CSF testing showing reduced
concentrations of amyloid-b42 (Motter et al., 1995; Olsson
et al., 2016) or amyloid-b42/amyloid-b40 (Slaets et al., 2013;
Toledo et al., 2013; Pannee et al., 2016). These methods
now have consensus appropriate use criteria (Johnson et al.,
2013; Shaw et al., 2018), are incorporated into current clin-
ical guidelines (National Institute for Health and Care
Excellence, 2018) and research criteria for Alzheimer’s dis-
ease diagnosis (Dubois et al., 2014; Jack et al., 2018), and
are increasingly used in clinical trials to either confirm
Alzheimer’s disease pathology in symptomatic individuals,
or to identify asymptomatic individuals at risk, who are
now defined as having preclinical Alzheimer’s disease.
However, amyloid PET is expensive, limited in accessibility
and involves ionizing radiation. CSF sampling is relatively
invasive, confers risk to individuals with coagulopathies, and
requires suitably trained personnel. As neither method is
likely to be viable for population-based screening, several
blood-based approaches have been developed.
A meta-analysis of studies published until 2015 (Olsson
et al., 2016) yielded conflicting results on the ability of
plasma amyloid-b to distinguish Alzheimer’s disease demen-
tia from controls, or mild cognitive impairment (MCI) pro-
gressing to Alzheimer’s disease dementia from stable MCI.
These mixed findings were related particularly to heterogen-
eity of comparisons; older studies compared clinically diag-
nosed Alzheimer’s disease cases with various non-
pathologically defined control groups, while newer studies
compared amyloid-positive and -negative groups as defined
by PET or CSF. Initially, methods used to quantify plasma
amyloid-b also lacked sensitivity, but from 2016 onward,
highly sensitive immunoassays and high-throughput mass
spectrometry methods were developed for measuring
plasma amyloid-b. Several studies, utilizing either of these
methods, probed the ability of blood-based assays to distin-
guish individuals with in vivo gold standard biomarker evi-
dence of Alzheimer pathology (i.e. either cortical amyloid
PET uptake or lowered CSF amyloid-b1-42 or amyloid-b1-42/
amyloid-b1-40) from controls without evidence of Alzheimer
pathology. Some publications focused on memory clinic
populations (mixed cohorts of cognitively healthy elderly
subjects, MCI and dementia), such as the Japanese National
Center for Geriatrics and Gerontology, the Australian
Imaging, Biomarker and Lifestyle Study of Ageing (Nakamura
et al., 2018), the Swedish BioFINDER study (Palmqvist et al.,
2018), and the Washington University cohort (Schindler et al.,
2019). Some studies specifically prospectively investigated indi-
viduals reporting subjective cognitive decline, such as the
Amsterdam Dementia Cohort (Verberk et al., 2018), and
Insight pre-AD (Vergallo et al., 2019). Taken together, in
memory clinic populations, plasma amyloid-b42/amyloid-b40
was able to predict concurrent PET or CSF amyloid status
with sensitivities of 70–76% and specificities of 72–78% (ac-
curacy varied from 68% to 97% across cohorts measured by
different assays). Plasma amyloid-b42/amyloid-b40 measured
by an immunoprecipitation–mass spectrometry (IP-MS)
method was also able to predict conversion from PET-negative
to PET-positive status more than 1.5 years later, with individu-
als who had plasma amyloid-b42/amyloid-b40 5 0.1218 being
15 times more likely to convert from PET-negative to PET-
positive than those above this cut-off point (Schindler et al.,
2019).
More recently, plasma phospho-tau181 (p-tau181) has
emerged as a potential biomarker of amyloid-b positivity,
with studies reporting an accuracy of 76–88% for predicting






/brain/article/144/2/434/6105867 by guest on 29 M
arch 2021
amyloid PET status (Mielke et al., 2018; Karikari et al.,
2020). Plasma p-tau181 may have some additive predictive
value with plasma amyloid-b42/40 measured by immunoassays
(Janelidze et al., 2020). Validation of these approaches has
largely focused on mixed cohorts (of individuals who are cog-
nitively normal, those with MCI and those with dementia).
Methods for identifying amyloid-b-positive individuals at
scale will take priority if disease-modifying therapies are
licensed. A key possible reason for the negative results seen
in many of the earlier amyloid-lowering therapy trials was
lack of biomarker evidence of Alzheimer’s disease in the full
recruited study populations (Doody et al., 2014; Salloway
et al., 2014; Vandenberghe et al., 2016). More recent trials
have therefore turned to ensuring that participants have
Alzheimer’s pathology as defined by mutation carrier status
in dominantly inherited disease or by amyloid biomarkers.
Examining results of 4-year follow-up in the Dominantly
Inherited Alzheimer’s Network Trial Unit (DIAN-TU) study
of solanezumab and gantenerumab, where the presence of
Alzheimer’s disease was defined by mutation carrier status,
primary cognitive endpoints were not met (Bateman, 2020).
In mild symptomatic sporadic Alzheimer’s disease, the
ENGAGE trial of aducanumab also did not meet its primary
end point but the similarly designed EMERGE trial did
show benefit at 78 weeks (Biogen, 2019), which has led to a
submission for regulatory approval to the US Food and
Drug Administration. Among the key limitations of the
amyloid-lowering trials in even mild symptomatic sporadic
Alzheimer’s disease is the possibility that the window of op-
portunity for preventing cognitive decline in such individuals
has already passed. With primary prevention trials such as
the Anti-Amyloid Treatment in Asymptomatic Alzheimer
disease (A4) Study of solanezumab (Sperling et al., 2020)
aiming to target those who may still be in that window,
population screening for amyloid-b positivity will need to
shift focus to asymptomatic individuals.
The main aim of our study was therefore to compare dir-
ectly the ability of three blood-based candidates for detecting
cerebral amyloid-b deposition—liquid chromatography-mass
spectrometry (LC-MS) measures of plasma amyloid-b, and
single molecule array (Simoa) measures of plasma amyloid-b
and phospho-tau181—to determine amyloid PET status in a
population-based sample of dementia-free individuals at age
70 years, drawn from the longest continuously participat-
ing British birth cohort study. In addition, we assessed corre-
lations between biomarkers, probed associations of
demographic factors with blood biomarkers, and examined
the potential cost savings of deploying each screening
method across a range of amyloid PET-positivity prevalence.
Materials and methods
Study design and participants
The Medical Research Council (MRC) National Survey for
Health and Development (NSHD; the British 1946 birth cohort)
followed an initial sample of 5362 individuals from their birth
in mainland Britain during 1 week in March 1946, over 24
waves of data collection. Insight 46 is a prospective substudy of
502 members at age 69–71 years, undertaken at University
College London (UCL); previous publications have detailed the
eligibility criteria and substudy protocol (Lane et al., 2017), and
compared the characteristics of Insight 46 participants to those
of the larger NSHD cohort (James et al., 2018). Ethical approv-
al for Insight 46 was given by the National Research Ethics
Service Committee London (reference 14/LO/1173). All partici-
pants gave written informed consent according to the
Declaration of Helsinki.
Neuroimaging
Dynamic PET-MRI data were acquired simultaneously on a sin-
gle Biograph mMR 3 T PET-MRI scanner, as described previ-
ously (Lane et al., 2017). Amyloid-b burden was assessed by
analysing the PET data acquired at a 10-min period, 50 min
after intravenous injection of 370 MBq 18F-florbetapir. Global
standardized uptake value ratio (SUVR) was calculated by nor-
malizing the uptake in a predefined cortical region of interest
(Landau et al., 2013) to that in eroded subcortical white matter.
Amyloid PET status was obtained by fitting a two-component
Gaussian mixture model of SUVR in all participants with ad-
equate PET data, and taking the 99th percentile of the lower
(amyloid PET-negative) Gaussian as the cut-off point (SUVR =
0.61, equivalent to 17 centiloids). SUVR 5 0.61 was defined as
PET positive and SUVR 5 0.61 as PET negative. Although all
study assessments were designed to be completed in a single
day, 59 individuals (13.4% of those included in the analysis)
had their PET scans on a different day to blood sampling due to
PET tracer availability or scanner maintenance issues; the me-
dian delay between the blood test and the scan in these individu-
als was 0.131 years [interquartile range (IQR): 0.060–0.211
years].
Whole brain volume, subcortical white matter hyperintensity
volume and total intracranial volume were extracted from the
MRI data for use as covariates in models examining the associa-
tions of age with plasma amyloid-b biomarkers. Whole brain
volume was extracted from T1-weighted images using the auto-
mated Brain Multi-Atlas Propagation and Segmentation
(BMAPS) technique (Leung et al., 2011). Subcortical white mat-
ter hyperintensity volume was extracted from T1 and FLAIR
images using the automated Bayesian Model Selection (BaMoS)
algorithm (Sudre et al., 2015), which excludes infratentorial
regions, followed by visual quality control to exclude individuals
with white matter lesions characteristic of demyelination or
large cortical infarcts inappropriately segmented as subcortical
white matter hyperintensities. Total intracranial volume was
extracted using Statistical Parametric Mapping software version
12 (Malone et al., 2015).
Cognitive assessment
Neuropsychological testing (Lane et al., 2017; Lu et al., 2019)
included a summary measure of cognition [the Mini-Mental
State Examination (MMSE); Folstein et al., 1975], tests of epi-
sodic memory [Wechsler memory scale-revised logical memory
test (Wechsler, 1987) and 12-item Face-Name Associative
Memory Exam (FNAME-12); Papp et al., 2014], and processing
speed (Wechsler adult intelligence scale-revised digit symbol
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substitution test (DSS); Wechsler, 1981]. The preclinical
Alzheimer’s cognitive composite (PACC) was derived as the sum
of z-scores of the MMSE, delayed logical memory (LMD),
FNAME-12 and DSS (Lu et al., 2019). Participant and inform-
ant history of cognitive concerns and of prior neurological diag-
noses was also elicited. Dementia was defined by expert
consensus (informed by clinical history, informant history and
MMSE score 5 26). MCI was defined as participant or inform-
ant concern regarding participant’s cognition, and either LMD
score 51.5 standard deviations (SD) below the mean, or DSS
score 51.5 SD below the mean.
Blood sampling and processing
Non-fasted venous blood was sampled between 09:30 and
11:00 h, using a tourniquet and 21G or 23G butterfly needle
with a BD Vacutainer collecting system, into 8.5 ml gel separ-
ator serum tubes and 10 ml EDTA plasma tubes. Whole blood
was transported and centrifuged at room temperature, at 2000g
for 10 min, within 30 min of sampling. Plasma and serum
supernatant aliquots of 0.5 ml were stored in polypropylene
screw-top cryovials at –80C within 60 min of sampling.
APOE e4 genotyping of the single nucleotide polymorphisms
rs439358 and rs7412 (Rawle et al., 2018) was used to define
APOE e4 carrier status as carrier (one or two e4 alleles) or non-
carrier.
All blood assays were performed blinded to clinical
information.
Nomenclature for amyloid-b assays
Throughout this manuscript we refer to amyloid-b42 and amyl-
oid-b40 where assays do not specify the starting amino acid of
the relevant peptides, and to amyloid-b1-42 and amyloid-b1-40
where assays quantify the specific peptides starting at the first
amino acid residue of the amyloid-b sequence.
Simoa assays
Plasma amyloid-b40 and amyloid-b42
One 0.5 ml aliquot of plasma from each individual was thawed
to room temperature over 1 h and vortexed for 2 s. Next, 0.3
ml was pipetted into a 1.5 ml polypropylene tube for centrifuga-
tion at 13 000g for 10 min; 0.1 ml of the supernatant was pipet-
ted onto each of two plates, for analysing amyloid-b40 and
amyloid-b42, respectively. Samples were analysed in duplicate,
using the same batch of reagents (Simoa Ab40 and Ab42 kits),
on the same HD-1 Analyser (Quanterix) at UCL. Results were
accepted if the intra-assay coefficient of variation (CV) across
the duplicates was 515%. Run validation controls prepared
using stock peptide solutions from the kits indicated inter-assay
CV 5 30%.
Plasma p-tau181
Plasma p-tau181 was measured on the Simoa HD-1 instrument
at the University of Gothenburg (Quanterix) using a recently
published method that has been validated both analytically and
clinically (Benussi et al., 2020; Karikari et al., 2020). Briefly, the
assay used the p-tau181-specific monoclonal antibody AT270
for capture and the N-terminal mouse monoclonal antibody
Tau12 that binds the N-terminal epitope 6-QEFEVMEDHAGT-
18 on full-length human tau for detection. The calibrator was
recombinant full-length recombinant tau-441 phosphorylated
in vitro by glycogen synthase kinase 3b (#TO8-50FN,
SignalChem). The specificity of the assay for tau forms that con-
tain the indicated epitopes was previously demonstrated by
mass spectrometry (Karikari et al., 2020). All Insight 46 samples
measured above the assay’s lower limit of quantification of 1.0
pg/ml. For further details, see the Supplementary material.
LC-MS plasma amyloid-b assay
Extended methods are available in the Supplementary material.
Calibrators were prepared using recombinant amyloid-b1-38,
amyloid-b1-40 and amyloid-b1-42 (rPeptide) added to 8% bovine
serum albumin in phosphate-buffered saline. Recombinant
‘heavy’ peptides (15N-uniformly labelled amyloid-b1-38, amyloid-
b1-40 and amyloid-b1-42; rPeptide) were added to samples and
calibrators prior to preparation and used as internal standards.
Pooled plasma samples from the University of Gothenburg were
used to track assay performance over different days, and
showed inter-assay CV 5 5%.
After a single thaw, amyloid-b peptides were immunoprecipi-
tated from 0.25 ml of each sample, with anti-amyloid-b anti-
bodies 4G8 (epitope 17–27 in the amyloid-b sequence) and
6E10 (epitope 1–16, both antibodies from BioLegend) coupled
to DynabeadsTM M-280 Sheep Anti-Mouse IgG magnetic beads
(Thermo Fisher Scientific), performed using a KingFisherTM Flex
Purification System (Thermo Fisher Scientific). After immuno-
precipitation, eluates in 0.1 ml of 0.5% formic acid were vac-
uum centrifuged and stored at –80C.
Prior to liquid chromatography-tandem mass spectrometry
(LC-MS/MS), the dried eluates were resuspended in 20% aceto-
nitrile and 4% concentrated ammonia in water, and injected
into the LC-MS system (a Dionex UltiMate LC system and a
Thermo Scientific Q ExactiveTM Quadrupole-OrbitrapTM hybrid
mass spectrometer). Chromatographic separation was achieved
using basic mobile phases and a reversed-phase monolith col-
umn at a flow rate of 0.3 ml/min. The mass spectrometer, oper-
ating in parallel reaction monitoring mode, was set to isolate
the 4 + charge state precursors of the amyloid-b peptides.
Product ions specific for each precursor (Supplementary Table
1) were selected and summed to calculate the chromatographic
areas for each peptide and its corresponding internal standard.
The area ratio of each analyte to its internal standard was used
for quantification in samples and calibrators. Peptides analysed
included amyloid-b1-38, amyloid-b1-40, amyloid-b1-42 and amyl-
oid-b–3-40 (also known as APP669–711). An LC-MS composite
was also generated by taking the average of the z-scores of the
amyloid-b–3-40/amyloid-b1-42 and amyloid-b1-40/amyloid-b1-42
ratios, after the method of Nakamura et al. (2018).
Statistical analysis
Analyses were performed in Stata Version 14.2 (Stata
Corporation, Texas, USA).
Descriptive statistics
Mann-Whitney U-tests for non-normally distributed continuous
variables, Student’s t-test for normally distributed continuous
variables and v2 tests for categorical variables were used to
compare the amyloid PET-positive and PET-negative groups, for
all who had a high-quality amyloid scan.
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Inter-biomarker correlations
Correlations between blood biomarker values were assessed in
all individuals for whom blood biomarker data were available.
As blood biomarker values were positively skewed, logarithmic
transformation was used before assessing Pearson correlations
between assays.
Associations between blood biomarkers and
demographics, accounting for imaging outcomes
and cognition
For analyses of the associations of demographic factors with
blood biomarkers, individuals were included if they had a full
set of blood biomarker data, a high-quality amyloid PET scan,
and were dementia-free. Figure 2 shows the process of inclusion
and exclusion of participants to derive the dementia-free group.
Although all individuals were born in the same week, age at the
time of blood testing indicated time of attendance within the
testing period of 2.6 years. Associations of blood biomarkers
with age were tested using univariable linear regression, subse-
quently additionally adjusting for sex, APOE e4 carrier status,
SUVR, PACC, whole brain volume and subcortical white matter
hyperintensity volume. Models including whole brain volume or
subcortical white matter hyperintensity volume also adjusted for
total intracranial volume. Unadjusted differences in blood bio-
markers between the sexes were assessed by Mann-Whitney U-
tests. For all these analyses, the outcome variables were log-
transformed blood biomarkers or ratios, apart from the LC-MS
composite which was examined without transformation.
Linear regression was used to investigate the associations of
SUVR and APOE e4 carrier status, adjusted for age and sex,
with log-transformed blood biomarkers (or non-transformed
LC-MS composite) as the dependent variable. Possible inter-
active effects of sex and SUVR, sex and APOE e4 carrier status,
and SUVR and APOE e4 carrier status were investigated by
including appropriate interaction terms. Model assumptions of
linearity were checked by examination of residuals.
Blood biomarker concordance with
amyloid PET and relative costs of
screening
To assess the contribution of blood biomarkers to prediction of
binary amyloid PET status, logistic regression models were con-
structed using blood biomarkers as predictors, with and without
inclusion of age, sex and APOE e4 carrier status. The model
predictions were then used in receiver operating characteristics
(ROC) analyses and the areas under the ROC curves (AUC)
were compared using DeLong tests: The best model derived
from each assay platform was defined as having the highest
AUC. Plasma cut-off points were determined using Youden’s
index as provided by the output of the ROC analysis. The
resulting values of sensitivity and specificity were applied across
a range of 10–50% theoretical prevalence of amyloid PET posi-
tivity to calculate the positive and negative predictive values of
the blood test, the total number needed to screen by blood test,
and number proceeding to PET scan, to identify 100 amyloid
PET-positive individuals. These calculations were performed by
solving for the contents of the 2  2 table generated in each
case, using the equations shown in Fig. 1A. The relative costs of
screening programmes using the different blood tests were
examined by solving the equations in Fig. 1B, at different theor-
etical cost ratios of individual blood tests to PET scan, and
across a range of 10–50% theoretical prevalence of amyloid
PET positivity.
Sensitivity analyses
ROC analyses were performed for amyloid PET status within
APOE e4 subgroups (non-carrier versus carrier) and after fur-
ther excluding those with prior neurological diagnoses and those
who fulfilled criteria for MCI (Fig. 2). The contribution of time
between blood test and scan, and of educational attainment,
were also ascertained.
To examine whether the choice of amyloid PET cut-off point
significantly affected the performance of the best-performing un-
adjusted plasma tests, sensitivity analyses were undertaken using
a range of definitions of amyloid PET status either side of the
cut-off point of 0.61 that had previously been determined by
mixture modelling (SUVR cut-off points between 0.57 and
0.65), with recalculation of the Youden’s index plasma cut-off
point in each case.
Data availability




Of 502 participants assessed in Insight 46, 481 had a com-
plete set of blood biomarker data, 444 had a high-quality
amyloid PET scan, of whom 441 (92% of those with com-
plete blood biomarker data) were dementia-free (Fig. 2).
Table 1 summarizes the characteristics of all individuals
included in the analysis; 82 of 441 individuals (18.6%) were
amyloid PET positive. Compared with PET-negative individ-
uals, PET-positive individuals had lower MMSE (median
PET positive 29 versus PET negative 30, P = 0.018) and
PACC scores [mean (SD): –0.122 (0.726) versus 0.046
(0.668), P = 0.044], were more likely to be APOE e4 car-
riers (57.3% versus 22.0%, P5 0.0001), and had higher
whole brain volumes (median (IQR), ml: 1126 (1965–1187)
versus 1096 (1026–1153), P = 0.018). Supplementary Table
2 summarizes the characteristics of all dementia-free individ-
uals, including those with missing data, and all those
excluded from analysis.
Inter-biomarker correlations
Weak positive correlations were observed between Simoa
ln amyloid-b42 and LC-MS ln amyloid-b1-42 (r = 0.207,
P = 0.001), Simoa ln amyloid-b40 and LC-MS ln
amyloid-b1-40 (r = 0.406, P5 0.0001), and Simoa ln
amyloid-b42/amyloid-b40 and LC-MS ln amyloid-b1-42/
amyloid-b1-40 (r = 0.189, P = 0.003). Simoa ln p-tau181
was weakly negatively correlated with LC-MS ln
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Figure 1 Formulae. (A) Calculations for number needed to screen to obtain 100 amyloid PET-positive individuals. Sensitivity and specificity
are independent of prevalence, and are fixed once the cut-off point is chosen (e.g. at Youden’s index). If prevalence is specified, the first three sim-
ultaneous equations can be solved for B–D. The positive and negative predictive values of the plasma test and the number needed to screen can
then be calculated by the following three equations. (B) Calculations for relative cost of the screening programme. These calculations are based
on specified costs of an individual PET scan (x) and blood test (y), number needed to prescreen (NNS) with blood test and number proceeding
to scan (NPS), to obtain a specified number of amyloid PET-positive individuals (n) in the context of a known estimated population prevalence of
amyloid PET positivity (p). It is assumed that x and y include initial setup costs.
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Figure 2 Recruitment flow chart. The chart shows an overview of Insight 46 recruitment from the MRC NSHD and summary of blood bio-
marker data available [modified with permission (James et al., 2018) under the terms of the Creative Commons Attribution 4.0 International
Licence (http://creativecommons.org/licenses/by/4.0/)]. The derivation of the dementia free group (used for the main analyses) and the cognitively
normal group (used in the sensitivity analysis for prediction of amyloid PET status) is shown. Ab = amyloid-b.
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amyloid-b1-42 (r = –0.204, P = 0.001) and LC-MS ln
amyloid-b1-42/amyloid-b1-40 (r = –0.303, P5 0.0001)
but not with Simoa amyloid-b markers. All measured in-
dividual LC-MS amyloid-b markers were moderately
positively correlated (r = 0.547–0.698, P5 0.0001) and
the LC-MS composite was strongly negatively correlated
with LC-MS ln amyloid-b1-42/amyloid-b1-40 (r = –0.863,
P50.0001). Supplementary Table 3 provides Pearson
correlations across all measured biomarkers with
Bonferroni-corrected P-values.
Associations of demographic factors
with blood biomarkers
Significant sex differences were seen only for Simoa plasma
amyloid-b40 [median (IQR), pg/ml: females 282 (255–315)
versus males 296 (258–327), P = 0.025] as shown in
Supplementary Table 4.
All plasma amyloid-b species and ratios excepting Simoa
plasma amyloid-b40 showed significant associations with
age, even within the very narrow age range of this cohort.
The direction of the association was inconsistent between
the two methods; both Simoa plasma amyloid-b42 and
Simoa plasma amyloid-b42/amyloid-b40 were positively asso-
ciated with age, but the LC-MS measures were negatively
associated with age (excepting the composite which had a
positive association). For every year increase in age, there
was a 0.1 log-fold decrease in LC-MS amyloid-b1-42/amyl-
oid-b1-40, and a 0.2-fold increase in LC-MS composite.
Simoa plasma p-tau181 was also positively associated with
age, showing a 0.4 log-fold increase per year. These associa-
tions persisted despite adjustment for sex, APOE e4 carrier
status and SUVR, and were not attenuated by further








Age at blood sampling, years 70.7 (0.7) 70.6 (0.6) 0.521 70.7 (0.7)
Sex, % female 49.6 54.9 0.367 50.6
APOE e4 status, % carrier 22.0 57.3 50.0001 28.6
MMSE 30 (29, 30) 29 (28, 30) 0.018 30 (29, 30)
PACC (z-score) 0.046 (0.668) –0.122 (0.726) 0.044 0.015 (0.682)
Educational attainment by age 26, n (%) 0.571
No qualification 52 (14.5) 13 (15.9) 65 (14.7)
Vocational 18 (5.0) 5 (6.1) 23 (5.2)
O-level/equivalent 91 (25.4) 21 (25.6) 112 (25.4)
A-level/equivalent 129 (35.9) 29 (35.4) 159 (35.8)
Degree/equivalent 69 (19.2) 14 (17.1) 83 (18.8)
n (%) individuals with blood sample and
amyloid PET scan not done on same day
52 (14.5) 7 (8.5) 0.621 59 (13.4)
Time between blood sample and amyloid
PET scan for individuals who did not





0.672 0.131 [0.060, 0.211]
n = 59
Total intracranial volume, ml 1421 [1335, 1507] 1448 [1381, 1542] 0.076 1427 [1341, 1517]
Whole brain volume, ml 1096 [1026, 1153]
n = 357
1126 [1065, 1187] 0.018 1100 [1034, 1162]
n = 439




0.329 3.1 [1.6, 6.8]
n = 427
Serum creatinine, mmol/l 73 [63, 83] 73 [64, 87] 0.375 73 [63.5, 84]
Body mass index 27.4 [24.3, 30.4] 26.2 [24.1, 28.8] 0.054 27.3 [24.3, 30.2]
Simoa plasma Ab40, pg/ml 289 [255, 319] 285 [257, 328] 0.601 288 [256, 322]
Simoa plasma Ab42, pg/ml 19.9 [17.1, 22.6] 18.1 [15.5, 22.9] 0.011 19.6 [16.7, 22.7]
Simoa plasma Ab42/Ab40 0.068 [0.059, 0.078] 0.061 [0.052, 0.072] 0.001 0.066 [0.058, 0.077]
Simoa plasma p-tau181, pg/ml 8.5 [6.1, 12.2] 12.8 [9.2, 16.0] 50.0001 9.2 [6.4, 12.9]
LC-MS plasma Ab1-38, pg/ml 24.8 [21.6, 27.9] 24.5 [21.6, 28.7] 0.960 24.8 [21.6, 8.0]
LC-MS plasma Ab1-40, pg/ml 284 [255, 314] 285 [260, 311] 0.976 284 [257, 314]
LC-MS plasma Ab1-42, pg/ml 29.6 [24.9, 34.2] 23.7 [20.3, 27.2] 50.0001 28.6 [23.4, 33.3]
LC-MS plasma Ab–3-40, pg/ml 30.1 [24.4, 35.7] 29.9 [24.4, 34.9] 0.911 30.1 [24.4, 35.7]
LC-MS plasma Ab1-42/Ab1-40 0.104 [0.093, 0.116] 0.082 [0.075, 0.090] 50.0001 0.099 [0.087, 0.113]
LC-MS plasma composite –0.154 (0.736) 0.667 (0.718) 50.0001 –0.001 (0.799)
Values are expressed as mean (SD) for normally distributed variables, median [interquartile range] for skewed variables, and percentages for binary and categorical variables. The
significance of differences between amyloid PET-negative and PET-positive participants was determined by Mann-Whitney U-tests (for continuous variables excepting age and LC-MS
plasma composite), t-tests (for age and LC-MS plasma composite), two sample tests of proportions (for binary variables) and Kruskal-Wallis equality of proportions rank test (for
educational attainment). Ab = amyloid-b; MMSE = Mini-Mental State Examination; NFL = neurofilament light chain; NSHD = National Survey of Health and Development; PACC =
preclinical Alzheimer’s cognitive composite; p-tau181 = phospho-tau181; WMHV = white matter hyperintensity volume.
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adjustment for whole brain volume, subcortical white matter
hyperintensity volume or PACC (Supplementary Table 5).
Considering cerebral amyloid as a continuous variable
(SUVR), as expected higher SUVR was associated with
lower Simoa plasma amyloid-b42 and amyloid-b42/amyloid-
b40. Higher SUVR and being an APOE e4 carrier were
independently associated with lower LC-MS plasma amyl-
oid-b1-42, amyloid-b1-42/amyloid-b1-40 and higher composite
(Supplementary Table 6). A model incorporating age, sex,
APOE e4 carrier status and SUVR explained 1.2% of the
variance in Simoa amyloid-b42, 3.4% for amyloid-b42/amyl-
oid-b40 and 23.7% for p-tau181. For LC-MS methods this
model explained 29.2%, 23.0% and 22.4% of the variance
in amyloid-b1-42, amyloid-b1-42/amyloid-b1-40 and composite
respectively.
There were no significant interactions (at P5 0.05) be-
tween sex and SUVR, or sex and APOE e4 carrier status, in
their associations with the investigated blood biomarkers.
Time between blood sampling and scan did not have any
significant associations with blood biomarkers, or confound
their associations with SUVR.
Concordance with amyloid PET
status
Table 2 shows the AUC from ROC analyses for amyloid
PET status in dementia-free individuals incorporating blood
biomarkers as predictors, either alone or combined with age,
sex and APOE e4 carrier status. LC-MS amyloid-b1-42/amyl-
oid-b1-40 (AUC 0.817, 95% confidence interval 0.770–
0.864) and LC-MS composite (0.820, 0.775–0.866) per-
formed significantly better than the best-performing Simoa
biomarker (p-tau181: 0.707, 0.646–0.768; P = 0.002 and
P = 0.001, respectively) and also significantly better than a
model incorporating age, sex and APOE e4 carrier status
alone (0.695, 0.628–0.762; P = 0.004 and P = 0.002, re-
spectively). Inclusion of these covariates did not significantly
improve the performance of LC-MS amyloid-b1-42/amyloid-
b1-40 or LC-MS composite. Sensitivity analyses in cognitively
normal individuals without prior neurological conditions
showed similar results (Supplementary Table 7). Combining
Simoa p-tau181 with either Simoa or LC-MS amyloid-b did
not contribute significantly to model performance
(Supplementary Table 8). Further inclusion of educational
attainment and time between blood sampling and scan also
did not contribute significantly (data not shown). The best-
performing Simoa and LC-MS biomarkers all had better
concordance with amyloid PET status in APOE e4 non-car-
riers than carriers (Supplementary Table 9).
The percentage of individuals who were discordant for
plasma and PET ranged from 26% to 32% depending on
the plasma test used. Most discordant individuals were
‘plasma-positive, PET-negative’ using both the LC-MS bio-
markers [104/115 = 90.4% of individuals discordant for LC-
MS amyloid-b42/amyloid-b40 versus PET (Fig. 3C); and 124/
130 = 94.6% of individuals discordant for the LC-MS com-
posite versus PET (Fig. 3D)], but both types of discordance
were seen using the Simoa biomarkers (Fig. 3A and B). The
patterns were similar if different SUVR cut-off points were
used (Supplementary Tables 10–13).
Blood tests for screening prior to
amyloid PET scan
Table 3 shows the potential outcomes of screening with the
two best-performing biomarkers from each platform, in a
population with amyloid PET positivity prevalence similar
to Insight 46. Without plasma screening, 543 scans would
be required to obtain 100 amyloid PET-positive individuals.
Screening 940 individuals by using a base model of age, sex
and APOE e4 carrier status would reduce the number of
scans required to 266 (i.e. by 50.0%). Neither Simoa plasma
amyloid-b42/amyloid-b40 nor p-tau181 could outperform the
base model, allowing for 41.3% and 44.4% reduction in
scan numbers, respectively. However, screening 623 individ-
uals with LC-MS amyloid-b1-42/amyloid-b1-40 using a cut-off
point of 0.095 would reduce the number of scans required
to 243 (i.e. by 54.4%) and screening 588 individuals with
Table 2 AUC from ROC analyses of amyloid PET status
Predictor(s) Biomarker alone Biomarker + Age + sex + APOE e4 carrier status
AUC 95% CI AUC 95% CI
Age + sex + APOE e4 carrier status – – 0.695 0.628, 0.762
Simoa plasma Ab42/Ab40 0.620 0.548, 0.691 0.727 0.665, 0.788
Simoa plasma p-tau181 0.707 0.646, 0.768 0.778 0.727, 0.828
LC-MS plasma Ab1-42/Ab1-40 0.817
a,b 0.770, 0.864 0.841c 0.796, 0.886
LC-MS plasma composite 0.820b,d 0.775, 0.866 0.843c 0.798, 0.887
The results of analyses using the two best performing blood biomarkers from each platform are shown. Models incorporated blood biomarkers with and without inclusion of age,
sex and APOE e4 carrier status, in dementia-free individuals (n = 441).
DeLong test results indicated where P5 0.05:
aP = 0.004 compared to age + sex + APOE e4 carrier status; P = 0.002 compared to Simoa plasma p-tau181.
bP 5 0.0001 compared to Simoa plasma Ab42/Ab40.
cP 5 0.0001 compared to age + sex + APOE e4 carrier status.
dP = 0.002 compared age + sex + APOE e4 carrier status; P = 0.001 compared to Simoa plasma p-tau181.
Ab = amyloid-b; AUC = area under the receiver operating characteristics curve; CI = confidence interval; p-tau181 = phospho-tau181.






/brain/article/144/2/434/6105867 by guest on 29 M
arch 2021
the LC-MS composite using a cut-off point of –0.049 would
reduce the number of scans required to 264 (i.e. by 50.4%).
Conversely, using multivariable models incorporating age,
sex and APOE e4 carrier status, LC-MS amyloid-b1-42/amyl-
oid-b1-40 and composite would allow the number of scans to
be reduced by 54.8% and 60.9%, respectively.
Extending the findings to hypothetical populations with
differing prevalence of amyloid PET positivity, Fig. 4 shows
that regardless of the screening test used, greater scan reduc-
tion would be afforded in populations with lower prevalence
of amyloid PET positivity. Of the two Simoa platform tests,
only plasma p-tau181 would have better negative predictive
value (NPV) than the base model, but neither Simoa test
would perform better than the base model in terms of posi-
tive predictive value (PPV) or scan reduction (Fig. 4A). The
greatest PPV and scan reduction would be afforded by LC-
MS amyloid-b1-42/amyloid-b1-40, while the NPV would be
greatest for the LC-MS composite (Fig. 4B). If added to age,
sex and APOE e4 carrier status, LC-MS composite would
have an improvement in PPV and scan reduction at the
expense of a worsening of NPV, whereas LC-MS amyloid-
b1-42/amyloid-b1-40 would have an improvement in NPV
without much change in PPV or scan reduction (Fig. 4D).
Relative costs of blood screening
Using the equations in Fig. 1, in a population of similar
prevalence of amyloid PET positivity to Insight 46, the LC-
MS amyloid-b1-42/amyloid-b1-40 test would yield the lowest
relative cost of screening with versus without using blood
tests (Fig. 5A) across a range of theoretical fractional costs of
individual blood tests compared to PET scans. However,
with higher prevalence of amyloid PET positivity, as may be
seen with increasing age, the screening programme would be
rendered less economical for a given blood test (Fig. 5B
shows the relationship with amyloid PET positivity for the
LC-MS amyloid-b1-42/amyloid-b1-40 test).
Discussion
In more than 400 dementia-free individuals of near-identical
age, we show that LC-MS methods for measuring plasma
Figure 3 Concordance of blood biomarkers with amyloid PET SUVR in dementia-free individuals in Insight 46 (n = 441). (A) ln
Simoa plasma amyloid-b42/amyloid-b40. (B) ln Simoa plasma p-tau181. (C) ln LC-MS plasma amyloid-b1-42/amyloid-b1-40. (D) LC-MS plasma com-
posite. Dashed vertical lines represent the SUVR cut-off point for PET positivity. Dashed horizontal lines represent the LC-MS biomarker cut-off
points corresponding with Youden’s index derived by ROC analyses. Concordant classification by PET and plasma is represented by the blue
area and discordant classification by the orange area on each graph. The non-log transformed cut-off points are 0.058 for Simoa plasma amyloid-
b42/amyloid-b40, 10.8 pg/ml for Simoa plasma p-tau181, 0.095 for LC-MS plasma amyloid-b1-42/amyloid-b1-40 and –0.049 for LC-MS plasma com-
posite. Ab = amyloid-b; p-tau181 = phospho-tau181.
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amyloid-b1-42/amyloid-b1-40 and a plasma composite outper-
form the Simoa amyloid-b42/amyloid-b40 and p-tau181
assays in their ability to discern amyloid PET status. Using
either LC-MS method to screen before PET scanning has the
potential to yield significant savings for clinical trial recruit-
ment, affording further reductions in the required number of
PET scans compared to the number of scans needed without
pre-screening or when using age, sex and APOE e4 carrier
status for screening.
Despite our cohort’s narrow age range, lower LC-MS
amyloid-b1-42/amyloid-b1-40 was associated with increased
age, and this was not attenuated by further adjustment for
PACC, white matter hyperintensity volume or whole brain
volume. A more age-diverse study (Schindler et al., 2019)
has reported a negative association, but its magnitude was
much smaller (a reduction of 3% per year of age). In our
age-restricted study it is therefore possible that this finding
either represents a true age effect, or reflects some other
source of variation between those attending near the start
and the end of the study (James et al., 2018), or both.
We found associations between APOE e4 carrier status
and LC-MS amyloid-b1-42 and amyloid-b1-42/amyloid-b1-40
independent of SUVR. However, while other groups using
mass spectrometry-based techniques for quantifying plasma
amyloid-b to predict cerebral amyloid status (Ovod et al.,
2017; Nakamura et al., 2018; Schindler et al., 2019) com-
monly included age and APOE e4 carrier status in predictive
models, we found that including these variables made no
material difference to the ability to predict amyloid status
when using LC-MS amyloid-b1-42/amyloid-b1-40, and only
small improvements using the LC-MS composite proposed
by Nakamura et al. (2018). Noting that amyloid PET results
are not routinely adjusted for APOE e4 carrier status, this
provides further confidence that the LC-MS assay is directly
reflecting brain amyloid-b. Our finding that the majority of
discordant cases were ‘plasma-positive, PET-negative’, and
this persisted despite changing the PET-positivity cut-off, is
consistent with prior studies showing similar results for
plasma (Schindler et al., 2019) and CSF (Palmqvist et al.,
2016), suggesting that as with CSF, plasma amyloid-b
markers may become abnormal before a threshold for cor-
tical amyloid-b positivity is reached.
Our results were not significantly altered by using different
PET cut-off points. However, Youden’s index cut-off points
for plasma amyloid-b, which we chose to maximize the com-
bination of sensitivity and specificity, may not be the most
useful in every screening setting. For example, in recruitment
to a clinical trial it may be desirable to choose a cut-off point
that maximizes sensitivity, although this increases the false
positive rate. In contrast, for population screening for































Age + sex + APOE e4
carrier status
57.3 78.3 74.4 940 266 272 50.0 –
Simoa plasma Ab42/Ab40 45.1 78.0 71.9 1192 314 224 41.3 –17.6
Simoa plasma p-tau181 70.7 68.3 68.7 762 297 241 44.4 –11.4
LC-MS plasma Ab1-42/
Ab1-40
86.6 71.9 74.6 623 243 295 54.4 8.5
LC-MS plasma composite 91.5 65.7 70.5 588 264 274 50.4 0.7
Simoa plasma Ab42/Ab40
+ age + sex + APOE
e4 carrier status
68.3 72.1 71.4 794 280 258 47.4 –5.1
Simoa plasma p-tau181 +
age + sex + APOE e4
carrier status
90.2 52.4 59.4 596 331 207 38.1 –23.9
LC-MS plasma Ab1-42/
Ab1-40 + age + sex +
APOE e4 carrier status
86.6 72.1 74.8 620 241 297 54.8 9.2
LC-MS plasma composite
+ age + sex + APOE
e4 carrier status
76.8 81.1 80.3 697 207 331 60.9 21.7
Values for sensitivity, specificity and accuracy were obtained by using Youden’s index cut-off points from each model for discriminating amyloid PET-positive from PET-negative de-
mentia-free individuals (n = 441). The penultimate column shows the percentage of scans saved relative to the number of scans that would be required without screening in a popu-
lation with similar prevalence of amyloid PET-positivity to Insight 46 (18.6% prevalence of amyloid PET positivity would mean 538 scans would be required to obtain 100 amyloid
PET-positive individuals). The last column shows the percentage of scans saved relative to the base model incorporating age + sex + APOE e4 carrier status, where negative values
indicate worse screening test performance than the base model. Ab = amyloid-b; p-tau181 = phospho-tau181.
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Figure 5 Relative costs of screening programmes using different blood tests. (A) Using different blood tests, at fixed prevalence of
amyloid PET positivity. (B) Using LC-MS plasma amyloid-b1-42/amyloid-b1-40 over a range of 10–50% of theoretical prevalence of amyloid PET
positivity. Ab = amyloid-b; p-tau181 = phospho-tau181.
Figure 4 Hypothetical performance of the best-performing Simoa and LC-MS tests by prevalence of amyloid PET positivity.
(A) Simoa biomarker alone. (B) LC-MS biomarker alone. (C) Simoa biomarker + age + sex + APOE e4 carrier status. (D) LC-MS biomarker +
age + sex + APOE e4 carrier status. Lines were modelled by computing the positive (PPV) and negative predictive values (NPV) of the tests and
the scan reduction afforded at specified values of amyloid PET positivity prevalence over the range 10–50%, in 5% intervals. Scan reduction is the
percentage of scans saved relative to the number of scans that would be required without screening (calculated according to the specified preva-
lence of amyloid PET positivity). Solid lines show PPV, dashed lines show NPV and dotted lines show scan reduction. Ab = amyloid-b; p-
tau181 = phospho-tau181.
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clinical purposes it may be desirable to minimize false posi-
tives, even if at the expense of the false negative rate.
In addition to cost reduction, plasma testing may allow
for screening of more diverse populations at scale, and
reductions in screen failures, resulting in faster clinical trial
recruitment. We demonstrate that the greatest potential sav-
ings would be made at lower prevalence of amyloid-b posi-
tivity. The prevalence of amyloid PET positivity is highly
age-dependent; as shown in a 2015 meta-analysis it was
16% at 60 years, 23% at 70 years and 33% at 80 years
(Jansen et al., 2015). In more recent data from the Mayo
Clinic Study of Aging the prevalence was 18% at age 60–69
and 32% at age 70–79 (Roberts et al., 2018) and the former
figure is consistent with the prevalence of 18.6% we note in
Insight 46. As with any screening test, false positives will be
expected, and a general consideration with all amyloid bio-
marker studies of asymptomatic individuals is that progres-
sion from amyloid positivity to clinical signs or symptoms
may take many years (Vos et al., 2013; Donohue et al.,
2017; Roberts et al., 2018), so amyloid-positive individuals
may never develop cognitive symptoms in their lifetime. Any
use of plasma biomarker-based screening will require clear
protocols for counselling and communicating plasma test
results to prospective participants (Harkins et al., 2015),
including that a positive result is likely to require confirm-
ation with another more definitive modality (PET or CSF).
The accuracy of the Simoa plasma p-tau181 assay in pre-
dicting amyloid PET status in Insight 46 was lower than
that previously published in cohorts comprising mixed popu-
lations of cognitively unimpaired individuals, MCI and
Alzheimer’s disease dementia; the AUC were 0.707 in
Insight 46, 0.881 in the Translational Biomarkers of Aging
and Dementia (TRIAD) cohort and 0.761 in the
BIOFINDER-2 cohort in which the same assay was used
(Karikari et al., 2020), and 0.79–0.81 in the BioFINDER-2
cohort in which a different Mesoscale Discovery assay was
used (Janelidze et al., 2020). In the TRIAD cohort, when
analysis was limited to cognitively unimpaired older individ-
uals, the AUC for prediction of amyloid PET status was
0.772. The differences observed may relate to differences in
amyloid PET tracers (18F-florbetapir in Insight 46, 18F-AZD-
4694 in TRIAD and 18F-flutemetamol in BioFINDER) but
may also be influenced by differences in the cohorts in terms
of burden of tau pathology, which is also highly correlated
with plasma p-tau181 (Mielke et al., 2018; Janelidze et al.,
2020; Karikari et al., 2020). As these cohorts had wider age
ranges, including some individuals up to a decade older than
those in Insight 46, amyloid PET-positive individuals in
those cohorts may have had a greater burden of cerebral tau
pathology at the time of blood sampling than those in
Insight 46, resulting in higher plasma p-tau181 levels. At
this phase of Insight 46 we did not have a measure of cere-
bral tau pathology such as tau PET, and therefore were not
able to investigate the relative predictive capacity of plasma
p-tau181 for amyloid PET versus tau PET. Since performing
our study, an immunoassay for plasma p-tau217 has been
developed that shows improved predictive capacity for
neuropathologically defined Alzheimer’s disease versus
non-Alzheimer’s disease dementias (AUC 0.98 for plasma
p-tau217 and 0.85 for plasma p-tau181), improved perform-
ance for biomarker-supported in vivo diagnosis of
Alzheimer’s disease versus non-Alzheimer’s disease (AUC
0.96 and 0.81 respectively), good concordance with cerebral
tau deposition defined by tau PET, and elevations in preseni-
lin-1 mutation carriers with presymptomatic dominantly
inherited Alzheimer’s disease compared to non-carriers
(Palmqvist et al., 2020). A mass spectrometry-based plasma
p-tau217 assay (Barthélemy et al., 2020) has also shown
good predictive capacity for CSF amyloid status in two
smaller cohorts consisting of a mixture of younger and older
controls, and individuals with cognitive impairment with
and without CSF amyloid pathology (AUC 0.92–0.99 for
plasma p-tau217 as opposed to 0.75–0.98 for plasma
p-tau181). Future work will therefore benefit from compar-
ing the plasma p-tau217 and p-tau181 assays in their utility
for predicting amyloid status in preclinical cohorts like
Insight 46.
While our study design has strengths, including general
population-representativeness at initial recruitment, direct
comparison of blood testing platforms, and concurrent pro-
spectively-collected plasma and PET amyloid data, we ac-
knowledge certain limitations. Our participants are
exclusively white British, so these findings cannot be
extrapolated directly to ethnically diverse populations. The
narrow age range of our study might also have underesti-
mated predictive capacity of models of amyloid PET status
that incorporated age, sex and APOE e4 carrier status.
Using global cortical amyloid PET as an outcome may
underestimate the true number of participants with cerebral
amyloid deposition, as CSF changes and region-specific
amyloid PET deposition (Palmqvist et al., 2016), may occur
earlier than when participants become ‘amyloid PET-posi-
tive’ by global cortical PET SUVR. CSF was not available
for this phase of data collection in Insight 46. Using CSF as
the comparator instead of PET might reduce the cost savings
of blood tests, as CSF testing is likely to be more economical
than PET, both in terms of initial setup and ongoing costs
(Wittenberg et al., 2019). Our assessment of the relative
costs of screening using blood tests is simplified, as it
absorbs any differences in setup costs between the two blood
test platforms into one theoretical cost estimate for each test.
Both platforms require expensive instruments and specialist
operators, and it is likely that real-world differences in setup
and maintenance costs would play an important role in
choosing one platform over another, in addition to differen-
ces in accuracy between platforms.
In conclusion, we demonstrate superior performance of
the LC-MS platform over Simoa assays for plasma amyloid-
b and p-tau181, and over a model incorporating age, sex
and APOE e4 carrier status, in screening for concurrent
PET amyloid status in a large number of dementia-free indi-
viduals. Our study strengthens a growing body of evidence
that plasma screening can reduce the numbers of amyloid
PET scans required to identify amyloid-b-positive
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individuals, for recruitment to clinical trials or ultimately for
giving anti-amyloid therapies, and suggests that this may be
feasible in a preclinical cohort.
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